New Health Economic analysis in France concludes there is insignificant cost difference between White Light and Blue Light Cystoscopy use when applying ccAFU guidelines
Press release – Oslo, Norway, October 6, 2023: Photocure ASA, The Bladder Cancer Company, announces the publication of “A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix[®] in patients diagnosed with non-muscle-invasive bladder cancer in France” in the peer-reviewed international Journal of Medical Economics this week. This health economic analysis aims to assess the financial impact of widely adopting Blue Light Cystoscopy (BLC[®]) as recommended in the French ccAFU guidelines. A budget impact model (BIM) was developed, that simulates the overall